Takeda Pharmaceutical Li...

NYSE: TAK · Real-Time Price · USD
14.97
0.17 (1.15%)
At close: Aug 15, 2025, 9:58 AM

Takeda Pharmaceutical Income Statement

Financials in JPY. Fiscal year is April - March.
Fiscal Year Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021
Revenue
1,053.4B 1,144.1B 1,176B 1,208B 1,050.9B 1,111.2B 1,043.1B 1,058.6B 956.16B 1,096.6B 1,002.3B 972.47B 873.29B 901.29B 844.82B 949.6B
Cost of Revenue
382.1B 416.87B 536.73B 549.78B 569.25B 379.48B 343.58B 321.11B 309.77B 335.97B 305.44B 292.88B 308.38B 281.4B 275.8B 241.26B
Gross Profit
671.3B 727.25B 639.31B 658.21B 481.62B 731.71B 699.51B 737.5B 646.38B 760.58B 696.86B 679.58B 564.91B 619.89B 569.02B 708.34B
Operating Income
-74.9B 66.94B 184.25B 219.71B 534M 104.91B -49.34B 168.57B 88.56B 146.99B 104.44B 150.51B -1.62B 116.48B 97.43B 248.55B
Interest Income
n/a n/a 4.12B 30.68B 5.99B 21.79B 9.36B 26.45B 7.78B 41.68B 14.78B 60.92B n/a 4.14B 6.86B 45.85B
Pretax Income
-107.3B 26.41B 119.37B 137.32B -51.26B 61.26B -95.98B 135.03B 47.91B 107.15B 64.55B 155.47B -54.05B 72.19B 61.45B 222.98B
Net Income
-103.2B 23.79B 92.05B 95.25B -3.02B 105.72B -48.03B 89.39B 31.13B 119.13B 61.74B 105.01B -11.36B 57.77B 45.96B 137.68B
Selling & General & Admin
295.9B 270.59B 268.28B 270.03B 285.23B 267.52B 252.95B 248.11B 254.8B 262.3B 248.73B 231.48B 223.43B 231.08B 212.01B 219.84B
Research & Development
216B 170.19B 175.56B 168.46B 195.86B 187.38B 183.95B 162.74B 160.94B 174.63B 154.15B 143.61B 143.63B 128.38B 131.6B 122.48B
Other Expenses
234.3B 219.53B n/a n/a n/a -1.21B n/a n/a n/a -1.01B n/a 153.98B 199.47B 143.95B 127.98B 117.46B
Operating Expenses
746.2B 660.31B 443.85B 438.49B 481.09B 665.29B 748.85B 568.93B 557.82B 613.59B 592.42B 529.07B 566.53B 503.4B 471.6B 459.79B
Interest Expense
n/a n/a 68.45B 59.69B 47.19B 66.57B 46.52B 59.58B 42.93B 79.75B 53.8B 55.47B n/a 46.71B 39.68B 71.07B
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
1,128.3B 1,077.2B 980.57B 988.28B 1,050.3B 1,044.8B 1,092.4B 890.05B 867.59B 949.56B 897.87B 821.95B 874.91B 784.81B 747.39B 701.05B
Income Tax Expense
-4.2B 2.57B 27.27B 41.3B -44.53B -44.5B -48.01B 45.63B 16.78B -12B 2.82B 50.45B -42.67B 14.37B 15.45B 85.25B
Shares Outstanding (Basic)
3.16B 3.17B 3.17B 3.14B 3.14B 3.14B 3.13B 3.11B 3.11B 3.11B 3.1B 3.09B 3.11B 3.13B 3.14B 3.09B
Shares Outstanding (Diluted)
3.16B 3.17B 3.22B 3.18B 3.14B 3.17B 3.13B 3.13B 3.23B 3.14B 3.13B 3.11B 3.15B 3.15B 3.16B 3.11B
EPS (Basic)
-32.62 7.51 29.07 30.36 -0.96 33.69 -15.34 28.76 10.02 38.32 19.89 33.97 -3.65 18.45 14.62 44.54
EPS (Diluted)
-32.62 7.51 28.59 29.97 -0.96 33.35 -15.34 28.56 9.65 37.93 19.74 33.78 -3.6 18.34 14.54 44.29
EBITDA
181.27B 193.01B 380.28B 384.55B 187.28B 291.98B 200.26B 347.9B 257.76B 323.87B 272.26B 323.04B 131.41B 263.77B 238.07B 391.55B
EBIT
-8.5B 6.05B 187.83B 196.29B -100.65B 127.83B -37.96B 194.61B 38.12B 186.9B 118.35B 210.94B -20.87B 118.9B 101.12B 294.05B
Depreciation & Amortization
189.77B 186.96B 192.45B 192.22B 186.74B 187.06B 240.24B 171.5B 161.41B 176.88B 167.83B 158.28B 152.27B 147.28B 140.65B 142.95B